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ABSTRACT 
The food enzyme considered in this opinion is a lipase (triacylglycerol lipase; EC 3.1.1.3) produced with a 
genetically modified strain of Aspergillus oryzae. The genetic modifications do not raise safety concern. The 
food enzyme contains neither the production organism nor recombinant DNA. The lipase is intended to be used 
in a number of food manufacturing processes, such as in baking and other cereal-based processes. The dietary 
exposure was assessed on the basis of data retrieved from the EFSA Comprehensive European Food 
Consumption Database. The food enzyme did not induce gene mutations in bacteria nor micronuclei in human 
peripheral blood lymphocytes. Therefore, there is no concern with respect to genotoxicity. The systemic toxicity 
was assessed by means of a 90-day subchronic oral toxicity study in rodents. A No Observed Adverse Effect 
Level was derived, which compared with the dietary exposure results in a sufficiently high Margin of Exposure. 
The allergenicity was evaluated by searching for similarity of the amino acid sequence to those of known 
allergens. The Panel considered that the likelihood of food allergic reactions to the enzyme is low and therefore 
does not raise safety concern. Based on the genetic modifications performed, the manufacturing process, the 
compositional and biochemical data provided and the toxicological studies, this food enzyme does not raise 
safety concern under the intended conditions of use. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following a request from the European Commission, the EFSA Panel on Food Contact Material, 
Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific opinion on 
the food enzyme lipase (triacylglycerol lipase; EC 3.1.1.3) produced with the genetically modified 
Aspergillus oryzae strain NZYM-LH. 
The A. oryzae parental strain has a long history of use for the production of food enzymes. It has been 
modified in order to produce and secrete  lipase and to prevent or decrease the production of 
undesirable secondary metabolites. The genetic modifications do not raise safety concern.  
The food enzyme contains neither the production organism nor recombinant DNA, given the limits of 
detection. 
The food enzyme has been characterised by determining the temperature and pH optima and the 
thermo-stability. Its composition is verified by measuring the content of protein, ash, water, heavy 
metals and Total Organic Solids. The A. oryzae parental strain has been modified in order to prevent 
the production of cyclopiazonic acid and to decrease the potential production of kojic acid. The 
absence of cyclopiazonic acid, β-nitropropionic acid and kojic acid was demonstrated, given the limits 
of detection. 
The food enzyme is intended to be used in a number food manufacturing processes, such as in baking 
and other cereal-based processes. The typical use and the use levels recommended for specific food 
processes have been provided. 
The estimated dietary exposure was calculated on the basis of data retrieved from the EFSA 
Comprehensive European Food Consumption Database. 
The genotoxicity of the food enzyme was assessed by means of two in vitro assays (gene mutations in 
bacteria and in vitro micronucleus assay). The food enzyme, produced with the genetically modified 
A. oryzae strain NZYM-LH, did not induce gene mutations in bacteria with or without metabolic 
activation when tested under the conditions employed in the study as presented by the applicant. 
Neither did it induce micronuclei in cultured human blood lymphocytes under the test conditions 
employed for this study. The systemic toxicity was assessed by means of a 90-day subchronic oral 
toxicity study in rodents. A No Observed Adverse Effect Level (NOAEL) was derived, which 
compared with the dietary exposure results in a sufficiently high Margin of Exposure.  
The CEF Panel considers that the likelihood of food allergic reactions to this lipase produced with this 
genetically modified strain of A. oryzae is low and therefore does not raise safety concern. 
Based on the genetic modifications performed, the manufacturing process, the compositional and 
biochemical data provided and the toxicological studies, the Panel concluded that this food enzyme 
does not raise safety concern under the intended conditions of use. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Only food enzymes included in the Union list may be placed on the market as such and used in foods, 
in accordance with the specifications and conditions of use provided for in Article 7 (2) of Regulation 
(EC) No 1332/2008
5 on food enzymes. According to Regulation (EC) No 1332/2008 on food 
enzymes, a food enzyme which falls within the scope of Regulation (EC) No 1829/2003
6 on 
genetically modified food and feed should be authorised in accordance with that Regulation as well as 
under this Regulation. 
An application has been introduced by the company Novozymes A/S for the authorisation of the food 
enzyme lipase from a genetically modified strain of Aspergillus oryzae (strain NZYM-LH). 
Following the requirements of Article 12.1 of Commission Regulation (EU) No 234/2011
7 
implementing Regulation (EC) No 1331/2008
8, the Commission has verified that the application falls 
within the scope of the food enzyme Regulation and contain all the elements required under Chapter II 
of that Regulation. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests the European Food Safety Authority to carry out the safety 
assessment on the food enzyme lipase from a genetically modified strain of Aspergillus oryzae (strain 
NZYM-LH) in accordance with the article 17.3 of Regulation (EC) No 1332/2008 on food enzymes. 
                                                      
5  Regulation (EC) No 1332/2008 of the European Parliament and of the Council of 16 December 2008 on Food Enzymes 
and Amending Council Directive 83/417/EEC, Council Regulation (EC) No 1493/199, Directive 2000/13/EC, Council 
Directive 2001/112/EC and Regulation (EC) No 258/97. OJ L 354, 31.12.2008, p. 7-15. 
6  Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically 
modified food and feed. OJ L 268, 18.10.2003 p. 1-23. 
7   Commission Regulation (EU) No 234/2011 of 10 March 2011 implementing Regulation (EC) No 1331/2008 of the 
European Parliament and of the Council establishing a common authorisation procedure for food additives, food enzymes 
and food flavourings. OJ L 64, 11.03.2011, p 15-24. 
8   Regulation (EC) No 1331/2008 of the European Parliament and of the Council of 16 December 2008 establishing a 
common authorisation procedure for food additives, food enzymes and food flavourings. OJ L 354, 31.12.2008, p 1-6. Lipase from Aspergillus oryzae strain NZYM-LH
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ASSESSMENT 
1.  Introduction 
Before January 2009 food enzymes other than those used as food additives were not regulated or were 
regulated as processing aids under the legislation of the Member States. On 20 January 2009 the 
Regulation (EC) No 1332/2008 on food enzymes entered into force. This Regulation applies to 
enzymes that are added to food to perform a technological function in the manufacture, processing, 
preparation, treatment, packaging, transport or storage of such food, including enzymes used as 
processing aids. The Regulation (EC) No 1331/2008 established Union procedures for the safety 
assessment and the authorisation procedure of food additives, food enzymes and food flavourings. The 
use of a food enzyme shall only be authorised if it is demonstrated that:  
(i)  it does not pose a safety concern to the health of the consumer at the level of use 
proposed;  
(ii)  there is a reasonable technological need, and  
(iii)  its use does not mislead the consumer.  
All food enzymes currently on the EU market and intended to remain on the market as well as all new 
food enzymes shall be subjected to a safety evaluation by the European Food Safety Authority (EFSA) 
and an approval via a Union list. 
The Guidance on submission of a dossier on a food enzyme for evaluation by EFSA (EFSA, 2009) 
lays down the administrative, technical and toxicological data required. 
In the case of enzymes produced with genetically modified microorganisms (GMM) the guidance on 
the risk assessment of GMM and their products intended for food and feed use (EFSA GMO Panel, 
2011) applies.  
The assessment of a GMM aims to evaluate the safety of the food enzyme related to the genetic 
modifications. This starts from the evaluation of the safety of the parental/recipient and donor strains, 
e.g. regarding their capability to produce undesirable metabolites. It also includes the assessment of 
the genetic modifications, specifically of the introduction of genes of concern and the genetic stability. 
Finally, the presence of the production organism and its recombinant DNA in the final product is 
assessed. Special attention is paid to the presence of any recombinant genes of concern (e.g. antibiotic 
resistance genes), introduced during the development of the production strain. If the absence of the 
production strain and the recombinant DNA has been confirmed, no extensive environmental risk 
assessment of the enzyme product is required. 
The following evaluation applies to the lipase (triacylglycerol lipase; EC 3.1.1.3) produced with a 
genetically modified A. oryzae strain NZYM-LH. 
2.  Information on existing authorisations and evaluations 
The applicant reports that the Danish and French authorities have evaluated and authorised the use of 
the food enzyme produced with the genetically modified A. oryzae, strain NZYM-LH for baking 
processes. The Danish authority also provided the conditions of use, including the dosages for specific 
foods that were up to a level of 400 LU
9/kg flour. 
                                                      
9 LU = Lipase Units (see Section 3.3) Lipase from Aspergillus oryzae strain NZYM-LH
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3.  Technical data 
3.1.  Identity of the food enzyme 
IUBMB nomenclature:   Triacylglycerol lipase  
Systematic name:   Triacylglycerol acylhydrolase  
Synonym: Lipase 
IUBMB No:   EC 3.1.1.3  
CAS No:   9001-62-1  
EINECS No:   232-619-9. 
3.2.  Chemical parameters 
The lipase produced with the genetically modified A. oryzae strain NZYM-LH is a single polypeptide 
chain of 317 amino acids. The molecular mass derived from the amino acid sequence was calculated 
to be 35.0 kDa. 
Data on the chemical parameters and the protein homogeneity status of the food enzyme have been 
provided for four food enzyme batches, three batches to be used for commercialisation and one batch 
(PPW 26090) used for the toxicological tests (Table 1).  
The average Total Organic Solids (TOS) of the four food enzyme batches was 9.7 % (w/w); the values 
ranged from 9.1 to 10.3 % (Table 1). TOS is a calculated value derived from 100 % minus % water 
minus % ash. The four food enzyme batches presented in Table 1 are concentrates without any added 
diluents.  
The average specific activity of the four food enzyme batches expressed as ratio enzyme activity/mg 
TOS was 0.108 KLU/mg TOS; the values ranged from 0.095 to 0.116 KLU/mg TOS (Table 1). 
Considering the low variability of the activities as well as the specific activities in the four food 
enzyme batches, the average activity/mg TOS value of 0.108 KLU/mg TOS was used for subsequent 
calculations. 
A. oryzae, as a species, is known to have the potential to produce undesirable secondary metabolites 
such as cyclopiazonic acid (CPA), β-nitropropionic acid (NPA) and kojic acid (KA) (Blumenthal, 
2004). Accordingly, these mycotoxins must be checked in the final food enzyme from A. oryzae 
(FAO/WHO, 2006). A. oryzae as a species belongs to the Aspergillus flavus group which is known to 
have a gene cascade for the biosynthesis of aflatoxins, but under any known fermentation conditions, 
A. oryzae strains never produced aflatoxins (Blumenthal, 2004; Lee et al., 1991). The parental strain 
has been modified by γ-irradiation mutagenesis, resulting in the deletion of gene clusters required for 
the synthesis of the mycotoxins cyclopiazonic acid (cpa) and aflatoxin (afl). UV irradiation 
mutagenesis resulted in a reduced potential (15 % of the original) to produce kojic acid. None of these 
three species-specific mycotoxins (CPA, NPA and KA) were detected in the food enzyme (Table 1) by 
mass spectrometry (LC-MS/MS).  
The protein homogeneity status of the food enzyme was also investigated by SDS-PAGE analysis. The 
apparent molecular mass based on this technique is about 36 kDa. The gels presented for the four food 
enzyme batches consistently showed a protein band corresponding to a molecular mass of about 36 
kDa. Lipase from Aspergillus oryzae strain NZYM-LH
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The food enzyme was tested for other enzyme activities, i.e. alpha-amylase, glucoamylase 
(amyloglucosidase) and protease activities, which were below the detection limits of the employed 
methods (Table 1). 
Table 1:  Compositional data of the food enzyme  
Parameter Unit  Batches 
    LGF 0029  LGF 0030  LGF 0031  PPW 26090
(a) 
Lipase activity  KLU/g batch
(b) 11.3  10.0  9.2  11.3 
Protein %  (w/w)  5.94  5.63  4.88  5.94 
Ash %  (w/w)  1.6  1.5  1.3  1.6 
Water %  (w/w)  88.7  89.4  89.0  88.1 
Total Organic 
Solids (TOS)
(c)  % (w/w)  9.7  9.1  9.7  10.3 
Activity/mg TOS  KLU/mg TOS  0.116  0.110  0.095  0.110 
Pb mg/kg  batch  ND
(d) ND
(d) ND
(d) ND
(d) 
As mg/kg  batch  ND
(d) 0.115 0.136  ND
(d) 
Cd mg/kg  batch  ND
(d) ND
(d) ND
(d) ND
(d) 
Hg mg/kg  batch  ND
(d) ND
(d) ND
(d) ND
(d) 
Antimicrobial 
activity   ND
(d) ND
(d) ND
(d) ND
(d) 
Production strain  CFU per g batch  NA
(e) NA
(e) NA
(e) ND
(d) 
Cyclopiazonic 
acid  mg/kg batch   ND
(d) ND
(d) ND
(d) ND
(d) 
Kojic acid  mg/kg batch   ND
(d) ND
(d) ND
(d) ND
(d) 
β-nitro propionic 
acid  mg/kg batch  ND
(d) ND
(d) ND
(d) ND
(d) 
Antifoam agents  mg/kg batch  393  354  110  398 
Alpha-amylase FAU(F)/g  batch
(f)  ND
(d) ND
(d) ND
(d) ND
(d) 
Glucoamylase AGU/g  batch
(g)  ND
(d) ND
(d) ND
(d) ND
(d) 
Protease HUT/g  batch
(h)  ND
(d) ND
(d) ND
(d) ND
(d) 
(a):  Batch used for the toxicological tests. 
(b):  KLU: Kilo Lipase Units (see Section 3.3). 
(c):  TOS calculated as 100 % - % water -% ash.  
(d): ND: Not detected: below the limits of detections (Pb: 0.5 mg/kg; As: 0.1 mg/kg; Cd: 0.05 mg/kg; Hg: 0.03 mg/kg; 
cyclopropionic acid: 0.100 mg/kg; kojic acid: the limits of detection ranged from 0.03 to 0.08 mg/kg; β-nitropropionic 
acid: 0.23 mg/kg for three batches, 0.20 mg/kg for batch LGF 0031; alpha-amylase: 0.34 FAU(F)/g; glucoamylase: 
0.825 AGU/g: protease: 196 HUT/g; antimicrobial activity: inhibition zone diameters ≤ 16 mm imply that the 
antimicrobial activity was absent (FAO/WHO, 2006)). 
(e):  NA: Not analysed. 
(f):   FAU(F): Fungal alpha-Amylase Units (relative to an internal enzyme standard “F”). 
(g): AGU:  AmyloGlucosidase Units. 
(h):  HUT: Hemoglobin Units Tyrosine. 
 
The food enzyme complies with the microbiological criteria as laid down in the general specifications 
and considerations for enzymes used in food processing (FAO/WHO, 2006), which stipulate that 
Escherichia coli and Salmonella species are absent in 25 g of sample and total coliforms are not more 
than 30 CFU (Colony Forming Units) per gram.  
The applicant has provided information on the identity of the antifoam agents and the Panel considers 
the use of these as of no safety concern. 
The provided data regarding compositional batch-to-batch-variability are considered sufficient. Table 
1 shows that the food enzyme batch PPW 26090 used for the toxicological assays has a similar Lipase from Aspergillus oryzae strain NZYM-LH
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activity/mg TOS, level of inorganic constituents and amount of antifoam agents in relation to the other 
three food enzyme batches (LGF). Consequently, this food enzyme batch (PPW 26090) is considered 
suitable for the toxicological testing.  
3.3.  Properties of the food enzyme 
Triacylglycerol lipases catalyse the hydrolysis of the ester linkages in triacylglycerols, thus resulting in 
the generation of free fatty acids, diacylglycerols, monoacylglycerols and glycerol. It also hydrolyses 
the sn-1-ester linkage of diacylphospholipids resulting in the formation of 2-acyl-1-lysophospholipid 
and free fatty acid. It does not require any co-factor. 
The enzymatic activity is quantified by using a pH-stat titration system and is expressed in Kilo Lipase 
Units/g (KLU/g). One LU is the amount of enzyme which releases 1 µmol of titratable butyric acid per 
minute under the given standard conditions (reaction conditions: pH = 7.0, T = 30 °C, reaction time, at 
least 1.5 minutes). One LU corresponds to the international definition of an enzyme unit. In the assay 
tributyrin is used as substrate. Its cleavage results in butyric acid formation, which cause a pH 
variation. The reaction rate, and therefore the enzyme activity, are determined by measuring the 
volume of titrant added to the reaction system per minute to keep the pH constant.   
The food enzyme has been characterised regarding its activity depending on temperature and pH. The 
lipase is active at temperatures up to 70 °C (with an optimum at approximately 40 °C at pH 6) and 
within the pH-range of 4 to 10 (with an optimum of about pH 8 at 30 °C). The thermo-stability of the 
lipase was tested over the range of 30 °C to 90 °C after a pre-incubation at the different temperatures 
at pH 6 for 30 minutes. The activity itself was measured under standard conditions. The food enzyme 
retained its activity at temperatures up to 50 °C. At higher temperatures, the food enzyme losses 
rapidly its activity (at 60 °C, 40 % residual activity, pre-incubation at pH 6 for 30 minutes) and above 
80 °C, no activity remains after 30 minutes. 
3.4.  Information on the source materials 
3.4.1.  Information relating to the genetically modified microorganism 
3.4.1.1.  Characteristics of the recipient and parental microorganisms  
The production organism is the fungus A.oryzae. A. oryzae strains are not qualified as QPS (Qualified 
Presumption of Safety) because of the potential of mycotoxin production (EFSA BIOHAZ, 2012). The 
parental strain, A. oryzae A1560, has a long history of use for the production of food enzymes. The 
recipient strain A. oryzae JaL830, has been developed from the parental strain, A. oryzae A1560, 
through a series of modification steps including classical mutagenesis and genetic modification (the 
latter not described for confidentiality reasons).  
The classical mutagenesis steps included γ-irradiation mutagenesis, resulting in the deletion of gene 
clusters required for the synthesis of the mycotoxins cyclopiazonic acid (cpa) and aflatoxin (afl), and 
UV irradiation mutagenesis, resulting in a drastically reduced potential (15 % of the original) to 
produce kojic acid. A Southern blot analysis confirmed the absence of antibiotic resistance genes 
which were used during the genetic modification of the recipient strain. 
3.4.1.2.  Characteristics of the donor organisms  
The plasmid vector used for the transformation of the recipient strain contained elements to 
control the expression of the gene of interest as well as ensure integration of the introduced DNA 
into the recipient strain chromosome. The DNA introduced into the recipient strain did not contain 
antibiotic resistance genes.  Lipase from Aspergillus oryzae strain NZYM-LH
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3.4.1.3.  Description of the genetic modification process  
The production strain A. oryzae NZYM-LH was developed from the recipient strain JaL830 through 
transformation with a plasmid vector and selection of the transformants on appropriate medium. 
The production strain differs from the recipient strain by the synthesis and secretion of lipase. 
3.4.1.4.  Safety aspects of the genetic modification: Information relating to the GMM and comparison 
of the GMM with its conventional counterpart  
In comparison to the parental strain A1560, the recipient strain has lost the potential to produce 
cyclopiazonic acid and has a reduced potential to produce kojic acid. 
The final production strain NZYM-LH differs from the recipient strain by the synthesis and secretion 
of lipase.  
The presence of the gene encoding lipase in the NZYM-LH strain was verified by Southern blot 
analysis; this indicated that multiple copies of the full-length gene were integrated in the chromosomal 
DNA of the recipient. In order to estimate the number of copies, a quantitative real-time PCR was 
carried out.  
Southern blot analysis of the DNA production strain from three independent enzyme preparation 
batches at the end of pilot scale fermentation confirmed the genetic stability of the genetic 
modifications. 
The genetic modifications do not raise safety concern. 
3.4.1.5.  Safety for the environment 
Neither the production strain nor its recombinant DNA were detected in the final product (see Section 
3.5.2). Accordingly, as the food enzyme belongs to Category 2 of the guidance on risk assessment of 
genetically modified microorganisms and their products (EFSA GMO Panel, 2011), environmental 
exposure to the genetically modified microorganism or its DNA is negligible and hence no further 
environmental risk assessment is required. 
3.5.  Manufacturing process 
The manufacturing process includes a fermentation process and downstream processing. A 
comprehensive dataset related to the manufacturing process including a flow diagram was provided. 
The food enzyme is manufactured according to the Food Hygiene Regulation (EC) No 852/2004
10. 
According to the applicant the manufacturing process is certified according to Food Safety Systems 
Certification 22000 (FSSC 22000) and ISO 9001.  
3.5.1.  Information relating to the fermentation process  
The food enzyme is produced by a pure culture in contained submerged fed-batch fermentation with 
conventional process controls in place. The identity and purity of the culture are checked at each 
transfer step from frozen vials to the end of fermentation.  
3.5.2.  Information relating to the downstream processing 
The downstream processing includes recovery, purification and concentration. The food enzyme 
produced is recovered from the fermentation broth after biomass separation via filtration. Further 
purification and concentration involve a series of filtration steps, including ultrafiltration and final 
germ filtration.  
                                                      
10   Regulation (EC) No 852/2004 of the European Parliament and of the Council of 29 April 2004 on the hygiene of food 
additives. OJ L 226, 25.6.2004, p. 3-21. Lipase from Aspergillus oryzae strain NZYM-LH
 
EFSA Journal 2014;12(7):3763                                                                                                                                
 
10
The production strain could not be detected in a test volume of 1 g of three independent liquid batches 
tested in triplicate by liquid culturing in non-selective medium for 4 days (for resuscitation) followed 
by growth on selective solid agar plates for 4 days at suitable temperature favouring the growth of the 
production strain. No recombinant DNA was detected starting with 1 g of three samples of the 
concentrated product before formulation obtained from three independent production batches and 
tested in triplicate. Analysis was performed by PCR, amplifying the recombinant fragment spanning 
the deletion of an endogenous gene specific for the strain lineage, introduced in the first genetic 
modification step of the parental strain. 
3.6.  Reaction and fate in food 
Triacylglycerol lipases catalyse the hydrolysis of the ester linkages in triacylglycerols. The hydrolysis 
of triacylglycerols results in the generation of free fatty acids, diacylglycerols, monoacylglycerols and 
glycerol. It also hydrolyses the sn-1-ester linkage of diacylphospholipids resulting in the formation of 
2-acyl-1-lysophospholipid and free fatty acid.  
The data and information provided indicate that the lipase is denatured during processing under the 
intended use conditions. The food enzyme was tested for other enzyme activities i.e. alpha-amylase, 
glucoamylase (amyloglucosidase) and protease activities, which were below the detection limits of the 
employed methods. Therefore, no unintended reaction products from the lipase and any side-activities 
are to be expected. 
3.7.  Case of need and intended conditions of use 
The food enzyme is intended to be used for baking and other cereals processes (Table 2).  
Table 2:   Typical uses and recommended maximum use levels of the food enzyme as provided by 
the applicant 
Process  Recommended dosage of the food enzyme 
Baking processes and other cereal-based processes  Up to 2.2 KLU/kg of flour or grain, corresponding to 
20.4 mg TOS/kg (2.2 KLU/0.108 KLU/mg TOS 
(0.108 is the average of the four batches)) 
 
In the baking process, the use of lipase is aimed to improve the characteristic of the dough (strength 
and stability) facilitating its handling. The food enzyme is added together with other raw materials 
during the dough formation step. 
In other cereal-based processes, like processing of products such as pasta, noodles and snacks, the use 
of lipase is aimed to improve the dough processability, to reduce oil uptake during frying and to 
accelerate the drying step, thereby shortening the process time.  
According to the applicant, the food enzyme is used at the minimum dosage necessary to achieve the 
desired reaction according to Good Manufacturing Practice. The dosage applied in practice by a food 
manufacturer depends on the particular process (see Table 2). 
4.  Dietary exposure 
The dietary exposure assessment is performed for the processes for which the food enzyme is intended 
to be used (Table 2). A maximum consumption of baked product in 17 countries of 23.3 g/kg bw/day 
was retrieved from the EFSA Comprehensive European Food Consumption Database
11. It was 
estimated that the baking process results (on average) in 140 g of final bakery product from 100 g of 
flour. Therefore, an intake of flour of 16.6 g/kg bw/day is calculated. 
                                                      
11EFSA Comprehensive European Food Consumption Database http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb. 
htm Lipase from Aspergillus oryzae strain NZYM-LH
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Taking into account the highest recommended dosage of the food enzyme, 2 200 LU per kilogram of 
flour, corresponding to 20.4 mg TOS, it is possible to obtain the estimated dietary exposure, which 
results in 0.339 mg TOS/kg bw/day (20.4 mg TOS/kg flour x 16.6 x 10
-3 kg flour/kg bw/day).  
In case the food enzyme is proposed for products particularly designed for infants or young children, 
ad hoc conservative exposure estimates must be made taking specifically into account these 
population groups. Otherwise, the very conservative approach described above, is considered to cover 
both adults and children. 
5.  Toxicological data 
The toxicological assays were performed with a food enzyme (batch PPW 26090, see Table 1) 
representative of the other three food enzyme batches. 
Genotoxicity testing 
In order to investigate the potential to induce gene mutations in bacteria, an Ames test was performed 
according to OECD Test Guideline 471 (OECD, 1997) and following Good Laboratory Practice 
(GLP) in four strains of Salmonella typhimurium (TA1535, TA100, TA1537, TA98) and Escherichia 
coli WP2uvrA, in the presence or absence of metabolic activation by S9 mix applying the “plate 
incorporation assay” for the E. coli strain and the “treat and plate assay” for the Salmonella strains. 
Two experiments were carried out using six different concentrations of the food enzyme, appropriate 
positive control chemicals and deionised water as solvent and negative control. The highest 
concentration was 5 000 µg dry matter (4 300 μg TOS) per ml incubation mixture (treat and plate 
assay) or per plate (plate incorporation assay). All positive control chemicals induced significant 
increases in revertant colony numbers, confirming the sensitivity of the tests and the efficacy of the S9 
mix, while the negative controls were within the normal ranges. Significant cytotoxicity, measured as 
the number of viable cells, was observed in one experiment with TA1537 in the presence of metabolic 
activation. Therefore, a further experiment was conducted with TA1537 in the presence of metabolic 
activation including treatments with a heat-inactivated sample of the test article. No toxicity was 
observed in treatments with the heat-inactivated sample in this third experiment but a concentration-
dependent increase in cytotoxicity was observed for the non-heat treated sample in this experiment. 
There were no signs of an increase in revertants at any concentration tested for all the five test strains 
in both the presence and absence of metabolic activation. Therefore, it was concluded that the food 
enzyme has no mutagenic activity, under the conditions employed.  
The in vitro micronucleus assay was carried out according to OECD Test Guideline 487 (OECD, 
2010) and following GLP. The food enzyme was tested in the in vitro micronucleus test using human 
peripheral blood lymphocytes both with and without metabolic activation with S9 mix. A maximum 
concentration of 5000 μg food enzyme/ml final culture concentration (corresponding to 515 μg 
TOS/ml final culture concentration) was selected for the Range-Finder Experiment. Concentrations for 
the Main Experiment were selected based on the results of this cytotoxicity Range-Finder Experiment. 
Purified water was used as solvent, and appropriate positive controls were included. Scoring was done 
with 1 000 cells in duplicate cultures. In experiment one, the highest concentration (5 000 μg food 
enzyme/ml culture, corresponding to 515 μg TOS/ml culture) in the absence and presence of metabolic 
activation induced approximately 0 % and 21 % reduction in replication index, respectively. There 
were no indications of an increase in micronucleated cells at the three tested concentrations compared 
to the vehicle control both in the absence and presence of metabolic activation. In experiment two, the 
highest concentration (5 000 μg food enzyme/ml culture, corresponding to 515 μg TOS/ml culture) in 
the absence and presence of metabolic activation, induced approximately 0 % and 15 % reduction in 
replication index, respectively. There were no indications of an increase in micronucleated cells at the 
three tested concentrations compared to the vehicle control both in the absence and presence of 
metabolic activation. It was concluded that the food enzyme did not induce chromosomal aberration in 
cultured human peripheral blood lymphocytes when tested up to 5  000 μg food enzyme/ml 
(corresponding to 515 μg TOS/ml) under the experimental conditions employed. Lipase from Aspergillus oryzae strain NZYM-LH
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Repeated dose toxicity testing: 
A 90-day subchronic oral toxicity study was performed according to OECD Test Guideline 408 and 
following GLP (OECD, 1998). Four groups of 10 male and 10 female SPF Sprague Dawley rats of the 
Ntac:SD strain were given by gavage a dose of 10 ml/kg bw/day tap water, a 10 % solution, a 33 % 
solution as well an undiluted stock solution of the food enzyme for 13 weeks. The doses were 
equivalent to 108, 357 and 1 080 mg TOS/kg bw/day. 
 
In open field observations it was noticed that females in the highest dose group showed statistically 
significant less time of moving, and also had a tendency for improper grasp response. However, these 
findings were isolated and of low magnitude and therefore they were not considered to be adverse. 
In haematology, a statistically significant decrease in the percentage of neutrophils and an increase in 
the percentage of lymphocytes were found in all male groups given the enzyme but there was no dose-
response between these groups. A statistically significant decrease in the number of neutrophils was 
measured in females in the low dose and in males in the low and medium dose groups. A significant 
higher percentage of eosinophils was seen in females of the medium dose group. These effects were 
observed sporadically, were not dose related and consequently, were not considered toxicologically 
significant. 
Blood analysis revealed that the aspartate aminotransferase activity in high dose males, as well as the 
potassium level in females of the medium dose group, were statistically significant lower than those of 
the control group. These effects were observed sporadically and were not dose related. 
Regarding the organ weight observations, the absolute brain weight in the low dose group of males 
only was statistically significantly lower than the control group. The observed statistically significant 
findings were not treatment related.  
Due to an experimental error, ophthalmoscopy was not performed at the end of the study as requested 
in the OECD guideline. Considering the absence of histopathological findings in the eyes, the missing 
ophthalmoscopy was not considered to affect the conclusion of the study.  
Based on the above mentioned observations, the Panel derived a NOAEL of the high dose level 1 080 
mg TOS/kg bw/day. 
6.  Allergenicity 
Potential allergenicity of lipase was assessed by comparing its amino acid sequence with those of 
known allergens according to the EFSA Scientific opinion on the assessment of allergenicity of GM 
plants and microorganisms and derived food and feed of the Scientific Panel on Genetically Modified 
Organisms (EFSA GMO Panel, 2010). Using higher than 35 % identity in a window of 80 amino acids 
as the criterion, no match was found. No food allergic reactions to lipase have been reported in the 
literature. 
 
Consequently, the CEF Panel considers that the likelihood of food allergic reactions to this lipase 
produced with this genetically modified strain of A. oryzae is low and therefore does not raise safety 
concerns. Lipase from Aspergillus oryzae strain NZYM-LH
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7.  Discussion 
The parental strain A. oryzae A1560 has a long history of use for the production of food enzymes. The 
recipient strain, JaL830, was developed from the parental strain through a series of modification steps 
including classical mutagenesis and genetic modification. The production strain NZYM-LH contains a 
recombinant gene encoding lipase.  Multiple copies were randomly integrated into the genomic DNA 
as part of the plasmid vector. The introduced trait is well-known and does not trigger a safety concern. 
No sequences that can cause safety concerns (e.g. antibiotic resistance genes) remained. Neither the 
production strain nor the recombinant genes are detected in the final products by methods considered 
adequate by the CEF Panel.  
The information provided on the manufacturing of the food enzyme, i.e. the fermentation conditions 
and the steps employed for isolation and purification, is considered sufficient. The available 
compositional data, including experimental evidence of the absence of potential contaminants such as 
mycotoxins, sufficiently demonstrate the identity and the purity of the food enzyme. The reported 
batch-to-batch variability is considered acceptable. 
 
The process conditions provided indicate that the enzyme is inactivated in the course of the intended 
applications. 
 
Dietary exposure estimates were calculated by assuming that the food enzyme is used at its maximum 
recommended dosage and the entire added food enzyme remains in the final food. Based on these 
assumptions and considering the total intake (Section 4), the estimated dietary exposure results to be 
0.339 mg TOS/kg bw/day. 
 
The food enzyme produced with the genetically modified A. oryzae strain NZYM-LH did not induce 
gene mutations in bacteria with or without metabolic activation. Neither did it induce chromosome 
aberrations in cultured human blood lymphocytes. Therefore, there is no concern with respect to 
genotoxicity. 
A comparison of the NOAEL (1 080 mg TOS/kg bw/day) from the 90-day study with the estimated 
dietary exposure, calculated to be 0.339 mg TOS/kg bw/day, results in a margin of exposure (MOE) of 
3 186, which is found sufficient. 
The CEF Panel considers that the likelihood of food allergic reactions to this lipase from this 
genetically modified strain of A. oryzae is low and therefore does not raise safety concerns. 
CONCLUSIONS 
Based on the genetic modifications performed, the manufacturing process, the compositional and 
biochemical data provided and findings in the toxicological studies, the food enzyme “Lipase from a 
genetically modified strain of Aspergillus oryzae (strain NZYM-LH)” does not raise a safety concern 
under the intended conditions of use. 
DOCUMENTATION PROVIDED TO EFSA 
Dossier “Lipase from a genetically modified strain of Aspergillus oryzae (strain NZYM-LH)”. 
November 2012. Submitted by Novozymes A/S. 
Additional information received by Novozymes A/S on August 2013. 
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ABBREVIATIONS 
Afl    aflatoxin 
AGU    AmyloGlucosidase  Units. 
bw    Body  weight 
CAS    Chemical  Abstracts  Service 
CFU    Colony  Forming  Units 
CPA    Cyclopiazonic  acid 
DNA    Deoxyribonucleic  acid 
EC      European Commission and Enzyme Commission 
EFSA      European Food Safety Authority 
EINECS    European Inventory of Existing Commercial Chemical Substances 
EU    European  Union 
FAU    Fungal  alpha-Amylase  Units 
FAO      Food and Agricultural Organisation 
GLP    Good  Laboratory  Practice 
GMM    Genetically  Modified  Micro-organisms 
GMO    Genetically  Modified  Organisms 
GMP    Good  Manufacturing  Practice 
HUT    Hemoglobin  Units  Tyrosine 
IUBMB    International Union of Biochemistry and Molecular Biology 
JECFA     Joint FAO/WHO Expert Committee on Food Additives 
KA    Kojic  acid 
KLU      Kilo Lipase Units  
LC-MS/MS    Liquid Chromatography/Tandem Mass Spectrometry 
LU    Lipase  Units 
MOE    Margin  of  Exposure 
MS    Mass  Spectrometry 
NOAEL    No Observed Adverse Effect Level 
NA    Not  Analysed 
ND      Not  Detected 
NPA     β-nitropropionic acid 
OECD    Organisation  for  Economic Cooperation and Development 
PCR    Polymerase  Chain  Reaction 
PS    Qualified  Presumption  of  Safety 
QPS    Qualified  Presumption  of  Safety 
SDS-PAGE    Sodium Dodecyl Sulphate-PolyAcrylamide Gel Electrophoresis 
TOS    Total  Organic  Solids 
WHO    World  Health  Organisation 